Non-Muscle Invasive Bladder Cancer

Global Non-Muscle Invasive Bladder Cancer Market to Reach US$8.9 Billion by 2030

The global market for Non-Muscle Invasive Bladder Cancer estimated at US$3.1 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 19.5% over the analysis period 2024-2030. Immunotherapy Treatment, one of the segments analyzed in the report, is expected to record a 18.9% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Chemotherapy Treatment segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$834.2 Million While China is Forecast to Grow at 26.2% CAGR

The Non-Muscle Invasive Bladder Cancer market in the U.S. is estimated at US$834.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 26.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.7% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.3% CAGR.

Global Non-Muscle Invasive Bladder Cancer Market – Key Trends & Drivers Summarized

Why Is Non-Muscle Invasive Bladder Cancer Drawing Focus in Urologic Oncology and Personalized Cancer Therapies?

Non-muscle invasive bladder cancer (NMIBC), which includes stages Ta, T1, and carcinoma in situ (CIS), represents nearly 70–75% of all newly diagnosed bladder cancer cases worldwide. Although these tumors are confined to the mucosa or submucosa of the bladder wall, their high recurrence rate and potential for progression make NMIBC a complex clinical challenge. The management of NMIBC requires precise surveillance, repeated interventions, and patient-tailored therapies to balance treatment efficacy with quality of life and cost burden.

The rising incidence of bladder cancer—particularly among older adults, smokers, and populations with occupational exposure to carcinogens—is elevating the clinical and economic significance of NMIBC. Urologists, oncologists, and health systems are emphasizing early detection, risk stratification, and maintenance therapies to delay or prevent progression to muscle-invasive disease. The integration of molecular diagnostics, advanced imaging, and non-invasive urine-based biomarkers is further improving diagnostic accuracy and surveillance efficiency. As treatment paradigms shift from invasive, generalized approaches to personalized intravesical immunotherapies and targeted agents, NMIBC is increasingly viewed as a high-priority segment within global oncology care.

How Are Immunotherapies, Intravesical Drug Delivery, and Biomarkers Transforming NMIBC Treatment?

Bacillus Calmette-Guérin (BCG) therapy remains the gold standard for high-risk NMIBC, but global shortages, intolerance, and treatment failures are prompting innovation in alternative intravesical agents. Novel immunotherapeutics such as N-803 (IL-15 agonist), checkpoint inhibitors (e.g., atezolizumab, pembrolizumab), and recombinant BCG strains are under advanced clinical development for BCG-unresponsive or refractory patients. These therapies aim to enhance anti-tumor immune activation within the bladder mucosa while minimizing systemic toxicity.

Drug delivery innovations—such as thermochemotherapy, sustained-release gels, and electromotive drug administration (EMDA)—are improving intravesical drug retention and mucosal penetration. Targeted agents like gene therapy vectors (e.g., nadofaragene firadenovec), epigenetic modulators, and FGFR inhibitors are showing promise in clinical trials. Molecular risk profiling and urine-based assays (e.g., UroVysion, Cxbladder) are supporting earlier detection of recurrence and guiding treatment intensity. These advances are positioning NMIBC therapy as a model of localized, immunologically-informed cancer management with high potential for therapeutic breakthroughs.

Which Patient Segments and Healthcare Systems Are Shaping Demand for NMIBC Therapeutics and Monitoring?

The primary patient population comprises individuals aged 60 and older, predominantly male, often with a history of tobacco use or exposure to industrial chemicals. Many NMIBC patients require lifelong surveillance due to the high recurrence risk, creating ongoing demand for cystoscopic follow-ups, imaging, and intravesical treatments. Intermediate- and high-risk patients—classified based on tumor size, multiplicity, and grade—drive demand for more aggressive immunotherapeutic and chemoablative regimens.

Geographically, North America and Western Europe dominate the NMIBC treatment landscape due to advanced urology infrastructure, reimbursement for BCG and cystoscopy, and robust clinical trial activity. Asia-Pacific is emerging as a fast-growing region with increasing bladder cancer prevalence and evolving access to advanced diagnostics and therapies. Countries like Japan, South Korea, and China are seeing expanded regulatory approvals and investments in oncology innovation. Low- and middle-income nations, meanwhile, are challenged by BCG access and delayed diagnosis but represent future growth opportunities through mobile diagnostics and bladder cancer awareness programs.

What Is Fueling Long-Term Growth and Innovation in the NMIBC Therapeutics Market?

The growth in the NMIBC therapeutics market is driven by unmet clinical needs, high recurrence burden, and the expanding pipeline of immuno-oncology and localized drug delivery platforms. As BCG shortages and treatment resistance become more prevalent, the opportunity for novel bladder-preserving therapies that reduce recurrence and progression risk is expanding. Regulatory pathways such as FDA’s accelerated approval for BCG-unresponsive NMIBC are encouraging biopharmaceutical innovation in this space.

Pharmaceutical firms are forming partnerships with urology societies, CROs, and hospital networks to accelerate intravesical drug development and expand access to clinical trials. Market growth is also supported by digital surveillance platforms, AI-based imaging analysis, and predictive biomarkers that improve recurrence detection and personalize treatment. With bladder preservation becoming a core therapeutic goal and patients demanding effective yet minimally invasive options, NMIBC will remain a dynamic, high-potential segment in the future of oncology therapeutics.

SCOPE OF STUDY:

The report analyzes the Non-Muscle Invasive Bladder Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Immunotherapy, Chemotherapy, Targeted Therapy); Cancer Type (Low Grade Bladder Cancer, High Grade Bladder Cancer); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AstraZeneca plc
• Bristol Myers Squibb Company
• CG Oncology
• Eli Lilly and Company
• Ferring Pharmaceuticals
• GlaxoSmithKline plc (GSK)
• Herantis Pharma Oyj
• ImmunityBio, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Protara Therapeutics, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sesen Bio, Inc.
• TARIS Biomedical LLC
• Theralase Technologies Inc.
• UroGen Pharma Ltd.
• Viventia Bio Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.